Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

120%

6 of 5 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 2(4)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04442048Phase 3Completed

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Role: collaborator

NCT05118724Phase 2Active Not Recruiting

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Role: collaborator

NCT03009058Phase 1Terminated

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Role: lead

NCT01539824Phase 2Completed

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

Role: lead

NCT03711188Phase 2Completed

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Role: lead

NCT01559818Phase 1Terminated

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Role: lead

NCT01303172Phase 2Completed

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Role: lead

NCT04137822Unknown

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Role: collaborator

NCT01308762Phase 1Completed

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Role: lead

All 9 trials loaded